143 related articles for article (PubMed ID: 20198329)
21. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.
Dietz AB; Souan L; Knutson GJ; Bulur PA; Litzow MR; Vuk-Pavlovic S
Blood; 2004 Aug; 104(4):1094-9. PubMed ID: 15100154
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutic effect of in vitro 5-aza-2'-deoxycytidine combined with imatinib on gastrointestinal stromal tumor].
Xiao H; Zheng HX; Wu LN; Liang G; Zhao YZ; Liang JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):266-70. PubMed ID: 22454175
[TBL] [Abstract][Full Text] [Related]
23. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
Miyoshi T; Nagai T; Ohmine K; Nakamura M; Kano Y; Muroi K; Komatsu N; Ozawa K
Biochem Pharmacol; 2005 Jun; 69(11):1585-94. PubMed ID: 15896338
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Triozzi PL; Aldrich W; Dombos C
Melanoma Res; 2008 Dec; 18(6):420-30. PubMed ID: 18971787
[TBL] [Abstract][Full Text] [Related]
25. Stage-specific effect of inhibition of autophagy on chemotherapy-induced cytotoxicity.
Shingu T; Fujiwara K; Bögler O; Akiyama Y; Moritake K; Shinojima N; Tamada Y; Yokoyama T; Kondo S
Autophagy; 2009 May; 5(4):537-9. PubMed ID: 19270491
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
27. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
28. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Jørgensen HG; Allan EK; Graham SM; Godden JL; Richmond L; Elliott MA; Mountford JC; Eaves CJ; Holyoake TL
Leukemia; 2005 Jul; 19(7):1184-91. PubMed ID: 15889158
[TBL] [Abstract][Full Text] [Related]
29. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
30. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model.
Merimsky O; Gorzalczany Y; Sagi-Eisenberg R
Int J Oncol; 2007 Jul; 31(1):225-32. PubMed ID: 17549426
[TBL] [Abstract][Full Text] [Related]
31. The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells.
Switalska M; Nasulewicz-Goldeman A; Opolska A; Maciejewska M; Kutner A; Wietrzyk J
Anticancer Drugs; 2012 Jan; 23(1):70-80. PubMed ID: 21934605
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
33. [Effect of phenylhexyl isothiocyanate on drug-resistance to imatinib in K562/G01 cell line].
Wu RJ; Huang YQ; Ma XD
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):149-52. PubMed ID: 23611223
[TBL] [Abstract][Full Text] [Related]
34. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
Tolomeo M; Grimaudo S; Di Cristina A; Pipitone RM; Dusonchet L; Meli M; Crosta L; Gebbia N; Invidiata FP; Titone L; Simoni D
Cancer Lett; 2008 Jul; 265(2):289-97. PubMed ID: 18374481
[TBL] [Abstract][Full Text] [Related]
35. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
[TBL] [Abstract][Full Text] [Related]
36. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
Vitali R; Mancini C; Cesi V; Tanno B; Mancuso M; Bossi G; Zhang Y; Martinez RV; Calabretta B; Dominici C; Raschellà G
Clin Cancer Res; 2008 Jul; 14(14):4622-30. PubMed ID: 18628477
[TBL] [Abstract][Full Text] [Related]
37. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer.
Bruce IA; Slevin NJ; Homer JJ; McGown AT; Ward TH
Anticancer Drugs; 2005 Aug; 16(7):719-26. PubMed ID: 16027519
[TBL] [Abstract][Full Text] [Related]
39. Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
Zhang LY; Huang JS; Pi ZM; Yu MY
Int J Clin Exp Pathol; 2015; 8(9):11340-7. PubMed ID: 26617858
[TBL] [Abstract][Full Text] [Related]
40. Erucic acid, a component of Lorenzo's oil and PPAR-δ ligand modifies C6 glioma growth and toxicity of doxorubicin. Experimental data and a comprehensive literature analysis.
Altinoz MA; Bilir A; Elmaci İ
Chem Biol Interact; 2018 Oct; 294():107-117. PubMed ID: 30142312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
